Triple Negative Breast Neoplasms

The supplied grounding does not support a single established cause or aetiology for triple-negative breast neoplasms. The literature instead emphasizes molecular heterogeneity and specific mutations or aberrant pathway activation in subsets of tumors.

The disease is characterized by loss of ER, PR, and HER2 expression, which removes responsiveness to endocrine and anti-HER2 approaches. The literature also links its biology to altered signaling pathways, tumor microenvironment interactions, drug resistance, cancer stem cells, and mechanisms of tumor escape, with specific attention to DNA repair, Wnt signaling, and immune checkpoint-related pathways.

The supplied grounding does not provide general patient-level risk factors for developing triple-negative breast neoplasms. It does note that some treatment-relevant subgroups include PD-L1-positive tumors and germline BRCA-mutated tumors.

Chemotherapy remains the standard of care, with surgery and radiotherapy also used in current treatment approaches. Because these tumors do not respond to endocrine therapy or HER2-targeted therapy, treatment development has focused on chemotherapy, immune checkpoint inhibitors, PARP inhibitors for selected BRCA-mutated disease, and other targeted therapies such as agents directed at DNA repair pathways, kinase signaling, and related molecular subtypes.